Timely Resolution of SARS-CoV-2-Related Multi-System Inflammatory Syndrome in Children

• DOI: 10.3390/v15010094
• Publication Date: 2022-12-30T10:15:53Z
• Authors: Daniel D. Reiff; Randy Q. Cron
• Keywords: Sequela

Background: Multisystem inflammatory syndrome in children (MIS-C) is a severe, postinfectious manifestation of coronavirus disease 2019 (COVID-19) the pediatric population. The manifested by hyperinflammation and can result cardiac dysfunction, coronary changes, end-organ damage. Adequate timely treatment prevent poor outcomes short term, but long-term data lacking. Methods: A large single center MIS-C cohort was followed longitudinally after with intravenous immunoglobulin (IVIG) ± glucocorticoids to determine natural history describe improvement laboratory markers outcomes. Patient were stratified severity compared. Results: 137 patients identified demographics similar previously described cohorts. Regardless severity, when adequately treated, initial lab abnormalities rapidly improved 6–8 month follow-up period, some resolved as little 1–2 weeks. Similarly, quickly treatment; all this months post-hospitalization. Conclusions: Although serious sequela COVID-19, treated aggressively, abnormalities, dilatation, systolic dysfunction improve minimal morbidity or mortality.